{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.736","upperLimit":"0.997","value":"0.938"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Objective response assessed using standard myeloma response criteria. Objective response is defined as a \\> 50% reduction in the quantitative IgM or M-Spike levels from baseline levels. Response must be documented by two measurements separated by at least 3 weeks.","dispersionType":"90% Confidence Interval","groups":[{"description":"Rituximab 375 mg/m2 day 1 of a 21-day cycle, followed by:\n\nCyclophosphamide 750 mg/m2 Doxorubicin 50 mg/m2 Vincristine 1.4 mg/m2 and Prednisone 100 mg/m2 daily","id":"OG000","title":"Rituximab + CHOP"}],"paramType":"NUMBER","populationDescription":"All eligible and treated patients are included in this analysis.","reportingStatus":"POSTED","timeFrame":"Every 3 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, every 12 months if patient is 6-10 years from study entry","title":"Objective Response to Treatment","type":"PRIMARY","unitOfMeasure":"proportion of participants"}